Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis

Tanta University

Status and phase: Enrolling; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: Pentoxifylline; Drug: Methotrexate

Study type: Interventional

Funder types: Other

Identifiers

NCT06998628

78956

Details and patient eligibility

About

Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) [9] i.e., 28 joints disease activity score (DAS 28) >2.6.
• Patients receiving the conventional DMARDs.
• Both sexes.
• Age range between 18and 70 years old

Exclusion criteria

• Patients with retinal or cerebral hemorrhage.
• Patients with renal and hepatic dysfunction.
• Patients with hypersensitivity to study medications.
• Pregnant and lactating females.
• Patients receiving biological or synthetic DMARDs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups

Control group

Active Comparator group

Description:

will receive the traditional therapy of RA for three months.

Treatment:

Drug: Methotrexate

Pentoxifylline group

Active Comparator group

Description:

will receive 400 mg pentoxifylline two times daily plus the traditional therapy of RA for three months.

Treatment:

Drug: Methotrexate

Drug: Pentoxifylline